Envestnet Asset Management Inc. Increases Stake in Supernus Pharmaceuticals, Inc. $SUPN

Envestnet Asset Management Inc. raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 50.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,525 shares of the specialty pharmaceutical company’s stock after purchasing an additional 30,256 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.16% of Supernus Pharmaceuticals worth $2,853,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Supernus Pharmaceuticals during the 1st quarter valued at approximately $41,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Supernus Pharmaceuticals during the 1st quarter valued at $46,000. GAMMA Investing LLC lifted its position in shares of Supernus Pharmaceuticals by 116.7% during the second quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock worth $90,000 after acquiring an additional 1,541 shares in the last quarter. CWM LLC boosted its holdings in shares of Supernus Pharmaceuticals by 92.4% in the second quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock worth $97,000 after acquiring an additional 1,479 shares during the period. Finally, Quantbot Technologies LP purchased a new position in shares of Supernus Pharmaceuticals in the first quarter valued at $103,000.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $45.00 on Monday. The company has a market capitalization of $2.58 billion, a P/E ratio of 39.13 and a beta of 0.75. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $57.65. The company has a fifty day moving average of $48.59 and a 200-day moving average of $40.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a net margin of 9.70% and a return on equity of 14.22%. The firm had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $175.82 million. During the same quarter in the previous year, the business earned $0.69 EPS. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. Supernus Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 59,900 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the transaction, the chief executive officer directly owned 1,206,578 shares of the company’s stock, valued at approximately $61,016,649.46. This trade represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total transaction of $524,092.20. Following the completion of the sale, the chief financial officer owned 1,246 shares of the company’s stock, valued at approximately $55,434.54. The trade was a 90.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 209,915 shares of company stock worth $9,965,819 in the last quarter. 8.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SUPN. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. TD Cowen increased their price target on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Zacks Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 17th. Bank of America initiated coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They issued a “buy” rating and a $65.00 target price on the stock. Finally, Cantor Fitzgerald boosted their price target on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research report on Tuesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $63.25.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.